The state has enjoyed success funding and building life sciences companies, and the new Indiana Biosciences Research Institute should give it a further boost, according to panelists Friday at IBJ's Life Sciences Power Breakfast.
Lilly expects to soon announce late-stage clinical trial results for two biotech drugs designed to slow the inflammation caused by autoimmune diseases. By the end of the year, it will announce results for a third.
Hospital system tripled its profit last year by wooing patients to its physicians, trimming hospital and clinical staff by more than 400. The rating agency Moody's says things look even better in 2015.
Such companies as HealthPro, OkCopay and even large insurers like Anthem are helping doctors and hospitals create new ways to package and price health care services, relieving some of the price-raising effects of traditional health insurance.
To satisfy patients with high-deductible health plans, Northwest Radiology has introduced flat-rate pricing for its imaging scans. It’s a centuries-old concept among postal services, but for health care, it’s revolutionary.
The Indianapolis-based maker of genetically modified seed traits and weed killers said Thursday that it earned $409 million before interest, taxes, depreciation and amortization, down by 19 percent from the same quarter a year ago.
Things got quiet after a wave of hospital systems' acquiring physician practices swept through central Indiana from 2008 to 2011. But a new wave could start now that Congress passed the "doc fix" last week.
AIT Labs and its former executives have already incurred nearly $5 million defending themselves against charges by the U.S. Department of Labor that AIT founder Michael Evans sold the company to its employees in 2009 at an inflated price.